Dr. Tiu is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
40 Landsdowne Street
Cambridge, MA 02139- Is this information wrong?
Summary
- I am a physician scientist who specializes in hematology, oncology and internal medicine with more than 20 years of combined clinical and research experience in the treatment and management of patients with cancer and other medical conditions. I received my board certifications in hematology and oncology in 2010 and in internal medicine in 2006. I have extensive research experience spanning 20 years in clinical, translational and laboratory based research in both the pharmaceutical and academic settings at top medical and pharmaceutical institutions in the United States. It resulted in multiple patents, publications, and awards in the field of cancer and medicine.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010- Cleveland Clinic FoundationResidency, Internal Medicine, 2003 - 2006
University of Santo TomasClass of 2000
Certifications & Licensure
OH State Medical License 2006 - 2019
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011, 2013
Clinical Trials
- Alefacept in Patients With Relapsed/Refractory Aplastic Anemia Start of enrollment: 2011 May 01
Publications & Presentations
PubMed
- 49 citationsVenetoclax Plus Gilteritinib for-Mutated Relapsed/Refractory Acute Myeloid Leukemia.Naval Daver, Alexander E Perl, Joseph Maly, Mark Levis, Ellen Ritchie, Mark Litzow, James McCloskey, Catherine C Smith, Gary Schiller, Terrence Bradley, Ramon V Tiu, K...> ;Journal of Clinical Oncology. 2022 Dec 10
- 19 citationsClinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib.Alexander E Perl, Naoko Hosono, Pau Montesinos, Nikolai Podoltsev, Giovanni Martinelli, Nicki Panoskaltsis, Christian Recher, Catherine C Smith, Mark J Levis, Stephen ...> ;Blood Cancer Journal. 2022 May 30
- 10 citationsERK Inhibitor LY3214996-Based Treatment Strategies for RAS-Driven Lung Cancer.Jens Köhler, Yutong Zhao, Jiaqi Li, Prafulla C. Gokhale, Hong L. Tiv, Aine Knott, Margaret K. Wilkens, Kara M. Soroko, Mika Lin, Chiara Ambrogio, Monica Musteanu, Atsu...> ;Molecular Cancer Therapeutics. 2021 Feb 3
- Join now to see all
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
